Weirdly (uniquely?) for one of your links, there does appear to be a bit of substance to this one. The BMJ goes into further detail
here.
Two points to note are that:
1) The sub-contractor concerned, Ventavia, were only responsible for 1,000 participants (the full trial was 44,000), so 2 per cent (ish). Not enough to invalidate the trial.
2) I don't see any substance to the allegation that their trials results were "doctored up". The concerns highlighted by the whistleblower are:
- Participants placed in a hallway after injection and not being monitored by clinical staff
- Lack of timely follow-up of patients who experienced adverse events
- Protocol deviations not being reported
- Vaccines not being stored at proper temperatures
- Mislabelled laboratory specimens, and
- Targeting of Ventavia staff for reporting these types of problems.
So nothing about falsifying data, more poor practice. The "doctored up" headline may be more to do with the fact that your original link is from the Russian news agency, TASS... who may possibly not be quite impartial.
A second employee has then (quote from the link above)
told The BMJ that, shortly after Ventavia fired Jackson, Pfizer was notified of problems at Ventavia with the vaccine trial and that an audit took place.
Since Jackson reported problems with Ventavia to the FDA in September 2020, Pfizer has hired Ventavia as a research subcontractor on four other vaccine clinical trials
So, good that an audit has taken place, but questionable that Ventavia continue to work as a subcontractor on new projects.